Cargando…

Serum Exosomal microRNA-21, 222 and 124-3p as Noninvasive Predictive Biomarkers in Newly Diagnosed High-Grade Gliomas: A Prospective Study

SIMPLE SUMMARY: Diagnosis of relapse during post-surgery monitoring of patients with High-grade glioma is often challenging. This study was aimed to identify circulating biomarkers providing information about response to therapy and early diagnosis of progression during follow-up of these patients....

Descripción completa

Detalles Bibliográficos
Autores principales: Olioso, Debora, Caccese, Mario, Santangelo, Alessandra, Lippi, Giuseppe, Zagonel, Vittorina, Cabrini, Giulio, Lombardi, Giuseppe, Dechecchi, Maria Cristina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8232769/
https://www.ncbi.nlm.nih.gov/pubmed/34203979
http://dx.doi.org/10.3390/cancers13123006
_version_ 1783713708913983488
author Olioso, Debora
Caccese, Mario
Santangelo, Alessandra
Lippi, Giuseppe
Zagonel, Vittorina
Cabrini, Giulio
Lombardi, Giuseppe
Dechecchi, Maria Cristina
author_facet Olioso, Debora
Caccese, Mario
Santangelo, Alessandra
Lippi, Giuseppe
Zagonel, Vittorina
Cabrini, Giulio
Lombardi, Giuseppe
Dechecchi, Maria Cristina
author_sort Olioso, Debora
collection PubMed
description SIMPLE SUMMARY: Diagnosis of relapse during post-surgery monitoring of patients with High-grade glioma is often challenging. This study was aimed to identify circulating biomarkers providing information about response to therapy and early diagnosis of progression during follow-up of these patients. Our findings, showing upregulation of exosomal miRNAs associated with relapse represent a proof of principle that these biomarkers may be clinically useful tools for diagnosing and monitoring of gliomas. ABSTRACT: Background: High-grade gliomas (HGG) are malignant brain tumors associated with frequent recurrent disease. Clinical management of HGG patients is currently devoid of blood biomarkers for early diagnosis, monitoring therapeutic effects and predicting recurrence. Different circulating miRNAs, both free and associated with exosomes, are described in patients with HGG. We previously identified miR-21, miR-222 and miR-124-3p purified from serum exosomes as molecular signature to help pre-operative clinical diagnosis and grading of gliomas. The aim of the present study was to verify this signature as a tool to assess the effect of treatment and for the early identification of progression in newly diagnosed HGG patients. Material and Methods: Major inclusion criteria were newly diagnosed, histologically confirmed HGG patients, no prior chemotherapy, ECOG PS 0-2 and patients scheduled for radiochemotherapy with temozolomide as first-line treatment after surgery. RANO criteria were used for response assessment. Serum was collected at baseline and subsequently at each neuroradiological assessment. mir-21, -222 and -124-3p expression in serum exosomes was measured in all samples. Results: A total number of 57 patients were enrolled; 41 were male, 52 with glioblastoma and 5 with anaplastic astrocytoma; 18 received radical surgery. HGG patients with higher exosomal miRNA expression displayed a statistically significant lower progression-free survival and overall survival. Increased expression of miR-21, -222 and -124-3p during post-operative follow-up was associated with HGG progression. Conclusions: These data indicate that miR-21, -222 and -124-3p in serum exosomes may be useful molecular biomarkers for complementing clinical evaluation of early tumor progression during post-surgical therapy in patients with HGG.
format Online
Article
Text
id pubmed-8232769
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-82327692021-06-26 Serum Exosomal microRNA-21, 222 and 124-3p as Noninvasive Predictive Biomarkers in Newly Diagnosed High-Grade Gliomas: A Prospective Study Olioso, Debora Caccese, Mario Santangelo, Alessandra Lippi, Giuseppe Zagonel, Vittorina Cabrini, Giulio Lombardi, Giuseppe Dechecchi, Maria Cristina Cancers (Basel) Article SIMPLE SUMMARY: Diagnosis of relapse during post-surgery monitoring of patients with High-grade glioma is often challenging. This study was aimed to identify circulating biomarkers providing information about response to therapy and early diagnosis of progression during follow-up of these patients. Our findings, showing upregulation of exosomal miRNAs associated with relapse represent a proof of principle that these biomarkers may be clinically useful tools for diagnosing and monitoring of gliomas. ABSTRACT: Background: High-grade gliomas (HGG) are malignant brain tumors associated with frequent recurrent disease. Clinical management of HGG patients is currently devoid of blood biomarkers for early diagnosis, monitoring therapeutic effects and predicting recurrence. Different circulating miRNAs, both free and associated with exosomes, are described in patients with HGG. We previously identified miR-21, miR-222 and miR-124-3p purified from serum exosomes as molecular signature to help pre-operative clinical diagnosis and grading of gliomas. The aim of the present study was to verify this signature as a tool to assess the effect of treatment and for the early identification of progression in newly diagnosed HGG patients. Material and Methods: Major inclusion criteria were newly diagnosed, histologically confirmed HGG patients, no prior chemotherapy, ECOG PS 0-2 and patients scheduled for radiochemotherapy with temozolomide as first-line treatment after surgery. RANO criteria were used for response assessment. Serum was collected at baseline and subsequently at each neuroradiological assessment. mir-21, -222 and -124-3p expression in serum exosomes was measured in all samples. Results: A total number of 57 patients were enrolled; 41 were male, 52 with glioblastoma and 5 with anaplastic astrocytoma; 18 received radical surgery. HGG patients with higher exosomal miRNA expression displayed a statistically significant lower progression-free survival and overall survival. Increased expression of miR-21, -222 and -124-3p during post-operative follow-up was associated with HGG progression. Conclusions: These data indicate that miR-21, -222 and -124-3p in serum exosomes may be useful molecular biomarkers for complementing clinical evaluation of early tumor progression during post-surgical therapy in patients with HGG. MDPI 2021-06-15 /pmc/articles/PMC8232769/ /pubmed/34203979 http://dx.doi.org/10.3390/cancers13123006 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Olioso, Debora
Caccese, Mario
Santangelo, Alessandra
Lippi, Giuseppe
Zagonel, Vittorina
Cabrini, Giulio
Lombardi, Giuseppe
Dechecchi, Maria Cristina
Serum Exosomal microRNA-21, 222 and 124-3p as Noninvasive Predictive Biomarkers in Newly Diagnosed High-Grade Gliomas: A Prospective Study
title Serum Exosomal microRNA-21, 222 and 124-3p as Noninvasive Predictive Biomarkers in Newly Diagnosed High-Grade Gliomas: A Prospective Study
title_full Serum Exosomal microRNA-21, 222 and 124-3p as Noninvasive Predictive Biomarkers in Newly Diagnosed High-Grade Gliomas: A Prospective Study
title_fullStr Serum Exosomal microRNA-21, 222 and 124-3p as Noninvasive Predictive Biomarkers in Newly Diagnosed High-Grade Gliomas: A Prospective Study
title_full_unstemmed Serum Exosomal microRNA-21, 222 and 124-3p as Noninvasive Predictive Biomarkers in Newly Diagnosed High-Grade Gliomas: A Prospective Study
title_short Serum Exosomal microRNA-21, 222 and 124-3p as Noninvasive Predictive Biomarkers in Newly Diagnosed High-Grade Gliomas: A Prospective Study
title_sort serum exosomal microrna-21, 222 and 124-3p as noninvasive predictive biomarkers in newly diagnosed high-grade gliomas: a prospective study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8232769/
https://www.ncbi.nlm.nih.gov/pubmed/34203979
http://dx.doi.org/10.3390/cancers13123006
work_keys_str_mv AT oliosodebora serumexosomalmicrorna21222and1243pasnoninvasivepredictivebiomarkersinnewlydiagnosedhighgradegliomasaprospectivestudy
AT caccesemario serumexosomalmicrorna21222and1243pasnoninvasivepredictivebiomarkersinnewlydiagnosedhighgradegliomasaprospectivestudy
AT santangeloalessandra serumexosomalmicrorna21222and1243pasnoninvasivepredictivebiomarkersinnewlydiagnosedhighgradegliomasaprospectivestudy
AT lippigiuseppe serumexosomalmicrorna21222and1243pasnoninvasivepredictivebiomarkersinnewlydiagnosedhighgradegliomasaprospectivestudy
AT zagonelvittorina serumexosomalmicrorna21222and1243pasnoninvasivepredictivebiomarkersinnewlydiagnosedhighgradegliomasaprospectivestudy
AT cabrinigiulio serumexosomalmicrorna21222and1243pasnoninvasivepredictivebiomarkersinnewlydiagnosedhighgradegliomasaprospectivestudy
AT lombardigiuseppe serumexosomalmicrorna21222and1243pasnoninvasivepredictivebiomarkersinnewlydiagnosedhighgradegliomasaprospectivestudy
AT dechecchimariacristina serumexosomalmicrorna21222and1243pasnoninvasivepredictivebiomarkersinnewlydiagnosedhighgradegliomasaprospectivestudy